Concepedia

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma

Amit M. Oza, Sandro Pignata, Andrés Poveda, Mary McCormack, Andrew R. Clamp, Benjamin Schwartz, Jonathan D. Cheng, Xiaoyun Li, Kristy H. Campbell, P. Dodion,

Journal of Clinical Oncology · 2015 · 113 citations · 13 references

DOI

Abstract

Oral ridaforolimus shows encouraging activity in advanced endometrial cancer but is associated with significant toxicity. Inhibition of the PI3K/Akt/mTOR pathway may be a viable therapeutic target.

References

13

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Two pathogenetic types of endometrial carcinoma

Jan V. Bokhman · Gynecologic Oncology · 1983 · 2.5K citations

, , +6

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

Marcus E. Randall, Virginia L. Filiaci, Hyman B. Muss et al. · Journal of Clinical Oncology · 2005 · 866 citations · Full text

Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

Gini F. Fleming, Virginia L. Brunetto, David Cella et al. · Journal of Clinical Oncology · 2004 · 561 citations · Full text

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Amit M. Oza, Laurie Elit, Ming‐Sound Tsao et al. · Journal of Clinical Oncology · 2011 · 333 citations · Full text